Hanmi Seeks To Swim In 'Blue Oceans' As It Expands Globally
Undruggable Targets, Rare Diseases, New Modalities
At a recent forum in Seoul, an executive of Hanmi Pharmaceuticals, whose novel neutropenia drug has just received a US green light, shares why it is crucial to create "blue oceans" through global innovative drug development and how the Korean firm plans to challenge these markets.
